Every 10-Q that Theravance Biopharma, Inc. (TBPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TBPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TBPH filings page.
Theravance Biopharma reported second‑quarter 2026 total revenues of $20.7 million, down from $26.2 million a year earlier, as the prior‑year period included a one‑time $7.5 million China milestone. Core revenue from the Viatris collaboration on COPD drug YUPELRI grew to $20.7 million from $18.7 million, supported by YUPELRI net sales of $70.7 million versus $66.3 million.
The company posted a net loss of $5.9 million for the quarter, compared with net income of $54.8 million in 2025, when results included a $75.1 million gain on realized TRELEGY milestones. First‑half 2026 revenues were $38.4 million with a net loss of $10.8 million. Operating cash flow remained positive at $66.3 million, and cash, cash equivalents and marketable securities totaled roughly $442 million, supporting total shareholders’ equity of $289.7 million.
In March 2026, Phase 3 CYPRESS for ampreloxetine in symptomatic neurogenic orthostatic hypotension did not meet its primary endpoint; the program is being wound down, and the company has ceased accruing interest on the related future royalty liability. A major restructuring is underway, reducing workforce by about 50%, with $7.7 million restructuring expenses in the first half and an expected ~60% reduction in annual operating expenses versus 2025. In June 2026, Theravance agreed to be acquired by Zymeworks, with each share to receive $17.00 in cash plus one contingent value right, subject to shareholder and regulatory approvals, with closing targeted for the second half of 2026.
Theravance Biopharma’s first-quarter 2026 results show a sharp strategic pivot after a key trial setback. Revenue from the Viatris collaboration grew to $17.7 million, driven by YUPELRI, while net loss narrowed to $4.9 million compared with $13.6 million a year earlier.
YUPELRI net sales recorded by Viatris reached $62.4 million, up 7%, implying $21.9 million for Theravance’s 35% share. Cash, cash equivalents and marketable securities totaled about $394.7 million with no long-term debt, boosted by TRELEGY and YUPELRI milestones.
After the ampreloxetine Phase 3 CYPRESS study failed its primary endpoint, the company is winding down the program, cutting about 50% of its 90 employees and implementing a restructuring expected to reduce operating expenses by roughly 60% versus 2025 and deliver about $70 million in annualized savings from the third quarter of 2026. A Board Strategic Review Committee is actively evaluating alternatives, including a possible sale of the company, while Theravance concentrates on its commercial YUPELRI franchise and remaining TRELEGY milestone upside.
Theravance Biopharma reported Q3 2025 results. Revenue was $19.99 million, driven by the Viatris collaboration on YUPELRI. The quarter produced net income of $3.6 million (basic and diluted EPS $0.07) versus a loss a year ago.
For the first nine months, revenue reached $61.6 million and net income was $44.9 million (diluted EPS $0.88), reflecting a $75.1 million gain from the $225 million sale of future TRELEGY royalties and a $50 million milestone receipt tied to 2024 TRELEGY sales. Core operations remained loss-making with a $23.6 million loss from operations year to date.
Cash, cash equivalents and restricted cash rose to $175.6 million as of September 30, 2025. YUPELRI net sales recorded by Viatris were $71.4 million in Q3 (Theravance’s implied 35% share: $25.0 million), and a $7.5 million China approval milestone was recognized year to date. Several YUPELRI patent suits were settled, with licensed generic US entry no earlier than April 23, 2039; one case remains pending.
Theravance Biopharma reported a profitable second quarter driven by a large one-time gain from the sale of TRELEGY royalties. The company recognized a net gain of $75.137 million on the sale and reported net income of $54.835 million for the three months ended June 30, 2025. Total revenues were $26.195 million for the quarter, including $18.695 million from the Viatris collaboration and a $7.5 million China regulatory milestone recognized as licensing revenue.
Liquidity strengthened materially: cash, cash equivalents, and restricted cash rose to $282.8 million and total assets increased to $426.0 million. Total shareholders' equity was $224.8 million, reducing the accumulated deficit to $924.3 million. The company retains potential remaining milestone receipts from Royalty Pharma of up to $150.0 million and remains eligible for additional Viatris milestones and China-region royalties. Legal proceedings related to ANDA filings and patent litigation are ongoing, with several settlements announced but some cases still pending.